gevokizumab

Phase 3Monoclonal antibody

Institut de Recherches Internationales Servier

gevokizumab is one of 80 small molecule programs targeting Pyoderma Gangrenosum. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pyoderma GangrenosumActive, not recruiting

Autoimmune Inner Ear DiseaseActive, not recruiting

OsteoarthritisActive, not recruiting

UveitisActive, not recruiting

Pyoderma GangrenosumPhase 2

Active, not recruiting

Autoimmune Inner Ear DiseasePhase 2

Active, not recruiting

OsteoarthritisPreclinical

Active, not recruiting

UveitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

gevokizumab

Institut de Recherches Internationales Servier

Phase 3

3 2

Platelet Rich Plasma

ZZagazig University

Preclinical

25 3

Bayer Aspirin

Enbrel

2 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 7

Glucophage

Boehringer Ingelheim

Preclinical

1 8

Naproxen Sodium

Bayer

Preclinical

1 9

Benadryl

Ozone

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pyoderma Gangrenosum4 trials

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Terminated·XXOMA (US) LLC·Phase 3·NCT02315417·16 enrolled

Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum

Completed·XXOMA (US) LLC·Phase 2·NCT01882504·8 enrolled

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Terminated·XXOMA (US) LLC·Phase 3·NCT02326740·9 enrolled

Show 1 more trial

A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Terminated·XXOMA (US) LLC·Phase 3·NCT02318914·15 enrolled

Osteoarthritis3 trials

Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand

Completed·XXOMA (US) LLC·N/A·NCT02293564·312 enrolled

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Completed·XXOMA (US) LLC·Phase 2·NCT01882491·91 enrolled

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Completed·XXOMA (US) LLC·Phase 2·NCT01683396·87 enrolled

Uveitis3 trials

Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)

Terminated· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 3·NCT02375685·71 enrolled

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis

Terminated·XXOMA (US) LLC·Phase 3·NCT02258867·4 enrolled

Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)

Terminated· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 3·NCT01965145·84 enrolled

Renal Cancer1 trial

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Completed· Novartis logo

Novartis·Phase 1·NCT03798626·167 enrolled

Efficacy and Safety1 trial

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

Completed·XXOMA (US) LLC·Phase 2·NCT01498874·127 enrolled

2 more indications

Stage II/III Colon Cancer1 trial

A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

Withdrawn·NNSABP Foundation Inc·Phase 2·NCT05178576

Autoimmune Inner Ear Disease1 trial

The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease

Completed·XXOMA (US) LLC·Phase 2·NCT01950312·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for gevokizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gevokizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gevokizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut de Recherches Internationales Servier company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Institut de Recherches Internationales Servier

gevokizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pyoderma Gangrenosum4 trials

Osteoarthritis3 trials

Uveitis3 trials

Renal Cancer1 trial

Efficacy and Safety1 trial

Stage II/III Colon Cancer1 trial

Autoimmune Inner Ear Disease1 trial

References

Drug Info

Quick Facts

Related News